# DSIP (Delta Sleep-Inducing Peptide)

**Last Updated:** December 4, 2025
**Evidence Level:** OCEBM Level 4 (Russian approval, mixed Western data)
**Risk Profile:** LOW
**Russian Status:** Approved (Deltaran, 1998)

---

## What Is This?

DSIP is a brain peptide discovered in the 1970s that was thought to induce sleep — but that's actually an overstatement. It's NOT a sedative. Western studies show inconsistent sleep effects. However, it shows strong promise for **stress-related sleep issues and withdrawal states** (Russian data shows 97% improvement in opioid withdrawal). Think of it as a stress-modulator that may improve sleep quality, not a sleeping pill.

---

## Categories

`Sleep` · `Mood & Stress`

---

## Glossary

| Term | Meaning |
|------|---------|
| OCEBM | Oxford Centre for Evidence-Based Medicine — rates evidence quality |
| Delta sleep | Deep, restorative sleep (slow-wave sleep) — when most physical recovery happens |
| GH (Growth Hormone) | A hormone released mainly during deep sleep that aids recovery |
| Circadian rhythm | Your body's 24-hour biological clock that regulates sleep-wake cycles |
| Neuroendocrine | Relating to the interaction between the nervous system and hormones |
| Hypothalamus | The brain region that controls sleep, hormones, and stress responses |
| Limbic system | The emotional centre of the brain |

---

## Key Specifications

| Property | Value |
|----------|-------|
| Sequence | Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu |
| Molecular Weight | 848.8 g/mol |
| Half-life | ~15-30 minutes |
| Administration | SC, IM, Intranasal |
| Russian Brand | Deltaran |
| Location | Hypothalamus, limbic system |

---

## Important Context

**The name "Sleep-Inducing" overstates effects.** DSIP is NOT a sedative. Human sleep studies show inconsistent results. The strongest clinical signal is for **stress/withdrawal states**, not primary insomnia.

---

## Mechanism of Action

DSIP's mechanism remains surprisingly unclear despite decades of research, which tells you something important about the compound: it doesn't fit neatly into established neuropharmacological categories. The peptide appears naturally in the hypothalamus and limbic system, suggesting roles in sleep regulation, stress response, and neuroendocrine function. But "appears naturally" and "regulates function" are vague descriptions because the precise receptor targets and signalling cascades remain poorly characterised.

What DSIP doesn't do is more clear than what it does. It's not a GABA agonist like benzodiazepines, not a histamine antagonist like diphenhydramine, not a melatonin receptor agonist, not an orexin antagonist. It doesn't produce sedation in the pharmacological sense—users don't report feeling drowsy, impaired, or unable to function. Instead, effects are described as improved sleep architecture, better stress adaptation, and enhanced recovery—subtle modulation rather than forced sleep induction.

The neuroendocrine effects suggest DSIP influences growth hormone pulsatility and cortisol regulation, which makes sense given its natural presence in hypothalamic regions controlling both sleep and hormonal rhythms. The peptide may modulate delta wave sleep (hence the name), potentially enhancing the deep restorative stages where GH release and physical recovery occur. But these effects are modest, inconsistent across individuals, and nowhere near the dramatic "sleep-inducing" effect the name implies.

The strongest mechanistic signal comes from withdrawal research. The 97% improvement rate in opioid withdrawal symptoms from Russian data suggests DSIP affects stress-adaptation systems and possibly attenuates the hyperarousal, anxiety, and sleep disruption that define withdrawal states. This fits with a stress-modulation rather than sleep-induction framework: DSIP may help when sleep problems stem from excessive stress activation rather than primary sleep disorders.

---

## Clinical Evidence

The clinical evidence for DSIP divides sharply between Western skepticism and Russian enthusiasm, creating a literature that's difficult to interpret. Early Western studies from the 1970s and 1980s showed mixed results. One small trial reported 59% increase in sleep in some participants—a meaningful effect—but sample sizes were tiny and replication inconsistent. Studies in chronic insomnia showed short-term effects that didn't persist, leading many researchers to conclude DSIP was a disappointing hypnotic that didn't live up to its name.

Then there's the Russian data. Deltaran (pharmaceutical DSIP) received approval in Russia in 1998 for treating withdrawal states and stress-related disorders. The most striking finding: 97% of opioid-dependent patients showed improvement in withdrawal symptoms when treated with DSIP. This isn't subtle benefit—it's near-universal response in one of medicine's most difficult treatment challenges. Similar positive results appeared for alcohol withdrawal, where DSIP reduced craving, anxiety, and sleep disruption during acute detoxification.

The disconnect between Western and Russian findings is hard to reconcile. Different study populations, different formulations, different cultural contexts around drug approval—all complicate interpretation. What seems most likely is that DSIP works better in specific contexts (stress/withdrawal) than others (primary insomnia), and early Western trials tested the wrong populations with the wrong expectations.

The sleep architecture studies that did show effects revealed increases in delta wave sleep and slight improvements in sleep onset and efficiency. These changes were measurable on EEG but often didn't translate to dramatic subjective improvement—users reported sleeping "better" but not "dramatically better." For those seeking a knockout sleeping pill, DSIP disappointed. For those with stress-driven sleep issues or seeking subtle optimization of sleep quality, effects were more promising.

The growth hormone connection adds another layer. Some users report deeper sleep and better recovery, which aligns with enhanced nocturnal GH pulsatility. Athletes and biohackers interested in recovery optimization have explored DSIP for this potential, though controlled evidence is lacking. The effect, if real, is likely subtle—modest enhancement of natural GH release patterns rather than pharmacological elevation.

---

## Use Cases by Goal

DSIP works best when matched to the right problem. The strongest use case is stress-related sleep issues where the underlying driver is hyperarousal, anxiety, or inability to downregulate after stressful days. Here, DSIP's stress-modulation properties address root cause rather than forcing sleep through sedation. The protocol is straightforward: 100-200mcg subcutaneously 30-60 minutes before bed, used consistently for 4-8 weeks to assess response. Success looks like falling asleep more easily, staying asleep through the night, and waking more refreshed—not dramatic sedation but genuine improvement in sleep quality.

For withdrawal support, the evidence is strongest and the dosing higher. Russian protocols use 200-300mcg daily during acute withdrawal periods, with that remarkable 97% improvement rate in opioid withdrawal symptoms. This isn't a first-line treatment in Western medicine, but for individuals struggling with withdrawal-related insomnia and hyperarousal, DSIP represents an option worth considering under medical supervision.

The growth hormone optimization angle appeals to athletes and recovery-focused users. The rationale is mechanistically sound: if DSIP enhances delta wave sleep, and delta sleep is when GH pulses peak, then DSIP might optimize recovery. The protocol combines 100-200mcg DSIP with GH secretagogues like ipamorelin or CJC-1295, taken before bed. Evidence is anecdotal, effects are subtle, but some users report improved sleep depth and better next-day recovery.

For sleep cycle reset—particularly shift workers or those dealing with jet lag—DSIP's circadian modulation effects may help. The protocol uses 100-200mcg at the desired sleep time for 1-2 weeks, essentially training the body to associate DSIP administration with sleep onset at a new time. This works better for circadian misalignment than primary insomnia.

Where DSIP doesn't work: primary insomnia without stress component, situations requiring acute sedation, sleep apnea or other mechanical sleep disorders, and generally in people who already sleep well. The compound works at the margins—optimizing imperfect sleep, supporting stressed systems, enhancing recovery—not inducing sleep in those who genuinely can't sleep for structural or neurological reasons.

---

## Anecdotal Reports (User Experiences)

**Note:** These are unverified reports from online forums and should not be considered medical evidence.

| Use Case | User Reports |
|----------|--------------|
| Stress-related insomnia | *"Helpful for stress-related insomnia"*, *"Good for resetting sleep schedule"* |
| GH optimization | *"Sleep deeper, recovery better"* |
| Shift work/jet lag | *"Good for resetting after jet lag"* |
| Sleep quality | *"Sleep quality improved—more refreshed on waking"*, *"Vivid dreams, felt like deeper sleep"* |
| Reality check | *"Didn't notice much difference"*, *"Effects inconsistent night to night"*, *"Worked for first week then stopped"* |

---

## Who Responds Well vs. Poorly

| Profile | Response |
|---------|----------|
| Stress-related sleep issues | Good response |
| Withdrawal states | **Strong response** |
| Shift workers | Good response |
| GH optimization seekers | Reasonable response |
| **Primary insomnia (no stress)** | **Poor response** |
| **Those expecting sedation** | **Disappointed** |
| **Already good sleepers** | **No benefit** |

---

## Dosing

| Protocol | Dose | Timing |
|----------|------|--------|
| Conservative | 100mcg | 30-60 min before bed |
| Standard | 200mcg | 30-60 min before bed |
| Russian (Deltaran) | 300mcg | Intranasal |

### Routes

| Route | Notes |
|-------|-------|
| Subcutaneous | Most common research |
| Intramuscular | Alternative |
| Intranasal | Russian Deltaran |

### Sleep Stack

| Compound | Contribution |
|----------|--------------|
| DSIP | Delta sleep support |
| Glycine 3g | Sleep quality |
| Melatonin 0.5-1mg | Circadian timing |
| Magnesium | GABA support |

---

## User Experience Timeline

| Timeframe | Observation |
|-----------|-------------|
| Night 1-3 | Subtle or nothing |
| Week 1 | Possible sleep quality improvement |
| Week 2-4 | Full effect (if responding) |
| Ongoing | Consistent effect in responders |

---

## Side Effects

| Effect | Frequency |
|--------|-----------|
| Vivid dreams | Common (expected) |
| Next-day grogginess | Rare |
| Headache | Rare |

**No serious risks, dependence, tolerance, withdrawal, or organ toxicity reported in available human data; long-term data limited.**

---

## Contraindications

- Sleep apnea (won't help mechanical issue)
- Pregnancy/breastfeeding (no data)

---

## Risk Assessment

DSIP carries a low-risk profile based on available human data, though "available data" is the key qualifier—long-term safety studies don't exist, and Western clinical experience remains limited. What we do know is reassuring: no serious adverse events, no dependence or withdrawal, no organ toxicity, no hormonal disruption in the limited trials conducted. The peptide's short half-life (15-30 minutes) means it clears quickly, reducing the potential for accumulation or prolonged unwanted effects.

The main risk is mismatched expectations leading to inappropriate use. DSIP is not a sleeping pill. Using it as such—taking higher doses, combining it with other sedatives, expecting knockout sleep—sets up disappointment and potential misuse. The compound works best as part of a comprehensive sleep optimization strategy, not as a standalone rescue medication for acute insomnia.

The lack of Western pharmaceutical development suggests either modest commercial potential or concerns about efficacy that made further investment unappealing. No major pharmaceutical company pursued DSIP after initial research, which typically signals weak efficacy signals in Phase II trials. The Russian approval and continued use of Deltaran represents a divergent regulatory and clinical culture rather than hidden Western bias—if DSIP were dramatically effective for sleep, someone would have developed it commercially.

For individuals with stress-related sleep issues willing to try an investigational peptide with modest effects and low risk, DSIP represents a reasonable option. For those seeking powerful sleep induction or treatment of primary sleep disorders, conventional sleep medications with stronger evidence bases make more sense. The risk-benefit calculation favors DSIP in narrow contexts: stress-driven insomnia, withdrawal support, sleep optimization in already decent sleepers seeking marginal gains.

---

## Synergies and Stacking

DSIP stacks best with complementary sleep-supporting compounds that address different aspects of sleep architecture and circadian regulation. The classic combination uses DSIP for delta wave enhancement, glycine (3g) for sleep quality and NMDA modulation, melatonin (0.5-1mg) for circadian timing, and magnesium for GABA receptor support and muscle relaxation. Each compound addresses a different mechanism, creating additive rather than redundant effects.

For growth hormone optimization, DSIP combines with GH secretagogues like ipamorelin or CJC-1295 with mechanistic logic: DSIP may enhance the deep sleep stages when GH secretagogues drive pituitary GH release, potentially optimizing both the timing and amplitude of nocturnal GH pulses. This is the stack favored by athletes and recovery-focused users, though evidence is entirely anecdotal.

What doesn't stack well: DSIP with strong sedatives (benzodiazepines, Z-drugs) because the mechanisms don't complement and you risk masking DSIP's subtle effects with pharmaceutical sledgehammers. DSIP with stimulants is also counterproductive—taking DSIP while using high-dose caffeine or other wake-promoting drugs fights against the circadian modulation you're trying to achieve.

The timing considerations matter. DSIP works best taken 30-60 minutes before intended sleep time, ideally with other sleep-supporting compounds taken simultaneously. Consistency matters more than optimization—taking the stack at the same time each night reinforces circadian patterns more than varying doses and timing trying to find perfect parameters.

---

## Realistic Expectations

- **Not a sleeping pill**
- May improve sleep quality subtly
- Best as part of comprehensive sleep protocol
- Stronger signal for stress/withdrawal
- Results highly variable

---

## Limitations

1. **"Sleep-inducing" is a misnomer** - Not a sedative
2. **Inconsistent human results** - Many don't respond
3. **Context dependent** - Works better in stress/withdrawal
4. **Limited Western validation**

---

## References

1. Schoenenberger GA, Monnier M. Delta-sleep-inducing peptide. Proc Natl Acad Sci USA. 1977.
2. Graf MV, Kastin AJ. DSIP: a review. Neurosci Biobehav Rev. 1984.
3. Schneider-Helmert D. Effects of DSIP in man. Neuropsychobiology. 1983.
4. Russian Ministry of Health Deltaran registration. 1998.
5. Prudchenko IA, et al. DSIP in treatment of addictions. Eksp Klin Farmakol. 2012.
